T
Thomas F. Lüscher
Researcher at University of Zurich
Publications - 1613
Citations - 88517
Thomas F. Lüscher is an academic researcher from University of Zurich. The author has contributed to research in topics: Endothelium & Myocardial infarction. The author has an hindex of 134, co-authored 1560 publications receiving 79034 citations. Previous affiliations of Thomas F. Lüscher include University of Texas Southwestern Medical Center & Durham University.
Papers
More filters
Journal ArticleDOI
Transforming growth factor-β-dependent Wnt secretion controls myofibroblast formation and myocardial fibrosis progression in experimental autoimmune myocarditis
Przemyslaw Blyszczuk,Przemyslaw Blyszczuk,Björn Müller-Edenborn,Tomas Valenta,Elena Osto,Elena Osto,Mara Stellato,Silvia Behnke,Katharina Glatz,Konrad Basler,Thomas F. Lüscher,Oliver Distler,Urs Eriksson,Gabriela Kania +13 more
TL;DR: TAK1-mediated rapid Wnt protein secretion is identified as a novel downstream key mechanism of TGF-&bgr;-mediated myofibroblast differentiation and myocardial fibrosis progression in human and mouse myocarditis and might represent a promising therapeutic approach against iDCM.
Journal ArticleDOI
Obesity Is Associated With Tissue-Specific Activation of Renal Angiotensin-Converting Enzyme In Vivo Evidence for a Regulatory Role of Endothelin
Matthias Barton,R. Carmona,Henning Morawietz,Livius V. d’Uscio,Winfried Goettsch,Heinz Hillen,Christian C. Haudenschild,José Eduardo Krieger,Klaus Münter,Thomas Lattmann,Thomas F. Lüscher,Sidney Shaw +11 more
TL;DR: Obesity is associated with the activation of renal ACE in vivo independent of its mRNA expression and enhanced vascular contractility to angiotensin II, providing novel mechanisms by which ET antagonists may exert organ protection.
Journal ArticleDOI
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.
TL;DR: There is substantial evidence that therapy with clopidogrel, a specific antagonist of the platelet P2Y12 ADP-receptor, also leads to reductions in serum levels of CD40 ligand, C-reactive protein, P-selectin, and platelet—leukocyte aggregate formation.
Journal ArticleDOI
Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity
Nicola Schäfer,Christine Lohmann,Stephan Winnik,Lambertus J. van Tits,Melroy X. Miranda,Athanasios Vergopoulos,Frank Ruschitzka,Jürg Nussberger,Stefan Berger,Thomas F. Lüscher,François Verrey,Christian M. Matter +11 more
TL;DR: Obesity-induced endothelial dysfunction depends on the ‘endothelial’ MR and is mediated by an imbalance of oxidative stress-modulating mechanisms, therefore, MR antagonists may represent an attractive therapeutic strategy in the increasing population of obese patients to decrease vascular dysfunction and subsequent atherosclerotic complications.
Journal ArticleDOI
The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression
Melroy X. Miranda,Lambertus J. van Tits,Christine Lohmann,Tasneem Arsiwala,Stephan Winnik,Anne Tailleux,Sokrates Stein,Ana P. Gomes,Vipin Suri,James L. Ellis,Thomas A. Lutz,Michael O. Hottiger,David A. Sinclair,Johan Auwerx,Kristina Schoonjans,Bart Staels,Thomas F. Lüscher,Christian M. Matter +17 more
TL;DR: Reduction in Pcsk9 secretion is identified as a novel effect of Sirt1 activity and Ldlr is uncovered as a prerequisite for Sirt 1-mediated atheroprotection in mice.